9 results
In this research project we explore anti-nociception as a state of pain modulation. Our main objectives in utilizing the plasticity of the central pain pathways are to: (i) Shift individuals from a pro-nociceptive pain modulation profile to an anti-…
Main: To assess the effect of an early extra measles immunization between 6and 12 months of age on the development of humoral and cell-mediatedimmunity against measles following routine MMR immunization at 14months of age.Secundary:Determine effect…
The aim of this study is to investigate the immune response to a tetravalent MenACWY-TT vaccine in 10-, 12- and 15-year old children primed with the monovalent MenC-TT conjugate vaccine at a young age and to1. determine whether the MenC-specific…
To determine effect of early (re) vaccinations after the current intensive chemotherapy for ALL. We will determine if there is a difference in respons to conjugated (T cell dependent) and polysaccharide (T cell independent) vaccines. This may result…
The main purpose of this study is to determine the appropriate age (10, 12 or 15 years) for a second MenC conjugate (MenCC) vaccine immunization in Dutch children that received a primary MenCC vaccination at a young age. A conclusion will be based…
The objective of this study is to establish the (cost) effectiveness of transmural collaborative care including a Consultation Letter for the GP and duloxetine (TCCCL) versus Duloxetine in patients with depression that present themselves with (sub)…
The objective of this proposal is to investigate if duloxetine is effective as a third choice pain medication for treating chronic pain in OA compared to usual care. Furthermore, we will assess the cost-effectiveness of duloxetine treatment and if…
The aim of this study is to determine whether LNP023 is effective and safe for the treatment of PNH. LNP023 is compared to the Standard of Care (SOC) anti-C5 antibody treatment. The primary objectives are to:• Demonstrate superiority of LNP023…
The primary objective of this study is to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, andefficacy of ALXN1210 in pediatric patients with paroxysmal nocturnal hemoglobinuria (PNH).